Document:

Executed in 6 Parts
                                             Counterpart No. (   )

                              NATIONAL EQUITY TRUST
                        S&P 500 STRATEGY TRUST SERIES 19
                            REFERENCE TRUST AGREEMENT

     This  Reference  Trust  Agreement  dated  ________,  2003 among  Prudential
Investment   Management  Services  LLC,  as  Depositor,   Prudential  Securities
Incorporated,  as Portfolio Supervisor and The Bank of New York, as Trustee sets
forth certain  provisions in full and incorporates other provisions by reference
to the document entitled  "National Equity Trust, Trust Indenture and Agreement"
(the "Basic Agreement") dated February 2, 2000. Such provisions as are set forth
in full herein and such provisions as are incorporated by reference constitute a
single instrument (the "Indenture").

                                WITNESSETH THAT:

     In  consideration  of the  premises  and of the  mutual  agreements  herein
contained, the Depositor and the Trustee agree as follows: Part I.

                     STANDARD TERMS AND CONDITIONS OF TRUST

     Subject to the provisions of Part II hereof,  all the provisions  contained
in the Basic  Agreement are herein  incorporated  by reference in their entirety
and  shall be deemed  to be a part of this  instrument  as fully and to the same
extent as though said provisions had been set forth in full in this instrument.

A.   Article I, entitled "Definitions," shall be amended as follows:

(i)  Section  1.01-Definitions  shall be amended to add the following definition
     at the end thereof:

<PAGE>

                                      -2-

     "Portfolio  Supervisor" of the Trust shall have the meaning  assigned to it
in Part II of the Reference Trust Agreement.

B.   Article  III,  entitled  "Administration  of  Trust,"  shall be  amended as
     follows:

     (i) The third  paragraph of Section  3.05-Distribution  shall be amended by
deleting any reference to Depositor and replacing it with Portfolio Supervisor.

     (ii)  Section  3.14-Deferred  Sales  Charge  shall  be  amended  to add the
following sentences at the end thereof:

"References to Deferred Sales Charge in this Trust Indenture and Agreement shall
include any Creation and  Development  Fee  indicated  in the  prospectus  for a
Trust.  The  Creation  and  Development  Fee  shall be  payable  on each date so
designated  and in an amount  determined  as specified in the  prospectus  for a
Trust."

C.   Article VIII, entitled "Depositor," shall be amended as follows:

     (i) Section 8.07-Compensation shall be amended by deleting any reference to
Depositor and replacing it with Portfolio Supervisor.

D.   Article IX,  entitled  "Additional  Covenants;  Miscellaneous  Provisions,"
     shall be amended as follows:

     (i) The first sentence of Section 9.05 - Written Notice shall be amended by
deleting the language "Prudential Securities  Incorporated at One Seaport Plaza,
New  York,  New  York  10292"  and  replacing  it  with  "Prudential  Investment
Management LLC at 100 Mulberry Street,  Gateway Center Three, Newark, New Jersey
07102".

                                    Part II.

                     SPECIAL TERMS AND CONDITIONS OF TRUST

     The following special terms and conditions are hereby agreed to:

<PAGE>

                                      -3-

A.   The Trust is  denominated  National  Equity Trust,  S&P 500 Strategy  Trust
     Series 19.

B.   The Units of the Trust shall be subject to a deferred sales charge.

C.   The publicly traded stocks listed in Schedule A hereto are those which,
     subject to the terms of this Indenture, have been or are to be deposited in
     Trust under this Indenture as of the date hereof.

D.   The term "Depositor" shall mean Prudential  Investment  Management Services
     LLC.

E.   The  term  "Portfolio   Supervisor"   shall  mean   Prudential   Securities
     Incorporated.

F.   The aggregate number of Units referred to in Sections 2.03 and 9.01 of the
      Basic Agreement is          as of the date hereof.

G.   A Unit of the Trust is hereby declared initially equal to 1/     th of the
     Trust.

H.   The term "First Settlement Date" shall mean                        , 2003.

I.   The terms  "Computation  Day" and "Record Date" shall mean on the tenth day
     of            2003,          2003,        2003 and                2003.

J.   The term "Distribution Date" shall mean on the twenty-fifth  day
     of            2003,          2003,        2003 and                2003.

K.   The term "Termination Date" shall mean          , 2004.

L.   The Trustee's Annual Fee shall be $.90 (per 1,000 Units) for 49,999,999 and
     below  units  outstanding  $.84 (per  1,000  Units) on the next  50,000,000
     Units,  $.78 (per 1,000 Units) on the next 100,000,000  Units and $.66 (per
     1,000 Units) on Units in excess of 200,000,000  Units.  In calculating  the
     Trustee's annual fee, the fee applicable to the number of units outstanding
     shall apply to all units outstanding.

M.   The Depositor's  Portfolio  supervisory service fee shall be $.25 per 1,000
     Units.

               [Signatures and acknowledgments on separate pages]Exhibit 10.43

            [*] indicates that a confidential portion of the text of
                        this agreement has been omitted.

                                LICENSE AGREEMENT

     This License Agreement (this "Agreement"), effective as of February 1, 2002
(the "Effective Date"), is entered into by and between XOMA Ireland Limited, a
company with limited liability organized under the laws of the Republic of
Ireland having offices at Shannon Airport House, Shannon, County Clare, Ireland
(with its Affiliates, "XOMA"), and MorphoSys AG, a German company having offices
at Lena-Christ-Str. 48, 82152 Martinsried/Planegg, Germany (with its Affiliates,
"MORPHOSYS").

                                   BACKGROUND

     A. XOMA is the owner or exclusive licensee of certain patent rights
relating to bacterial cell expression, and MORPHOSYS wishes to acquire
non-exclusive licenses under such patent rights; and

     B. XOMA is willing to grant MORPHOSYS non-exclusive licenses, on the terms
and conditions set forth below, in order to permit MORPHOSYS to engage in
certain research, development and commercial activities.

     NOW, THEREFORE, in consideration of the promises and the mutual covenants
hereinafter recited, the parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

     In this Agreement, the following terms shall have the meanings set forth in
this Article.

     1.1. "Affiliate" means any corporation or other entity which is directly or
indirectly controlling, controlled by or under common control with a party
hereto. For purposes of this Agreement, "control" (including, with correlative
meanings, the terms "controlled" and "controlling") means the possession,
directly or indirectly, of the power to direct or cause the direction of the
management or policies of the subject corporation or other entity, whether
through the ownership of voting securities, by agreement or otherwise.

     1.2. "Antibody Phage Display" means the authorized use of Licensed Antibody
Phage Display Materials to conduct Research and Development.

<PAGE>

     1.3. "Change in Control" means, with respect to a particular entity, any
transaction or series of transactions as a result of which any person or group
(as defined under the U.S. Securities Exchange Act of 1934, as amended) becomes,
directly or indirectly, the beneficial owner of more than fifty percent (50%) of
the total voting power of such entity's equity securities or otherwise gains
control of such entity.

     1.4. "Confidential Information" means any proprietary or confidential
information or material disclosed by a party to the other party pursuant to this
Agreement, which is (i) disclosed in tangible form hereunder and is designated
thereon as "Confidential" at the time it is delivered to the receiving party, or
(ii) disclosed orally hereunder and identified as confidential or proprietary
when disclosed and such disclosure of confidential information is confirmed in
writing within thirty (30) days by the disclosing party.

     1.5. "Dispose" means to transfer, assign, lease, or in any other fashion
dispose of control, ownership or possession, but shall not mean to license or
sell. "Disposition" shall have the correlative meaning.

     1.6. "Immunoglobulin" means any molecule, including without limitation,
full immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and
ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which
it specifically interacts with an antigen and wherein that amino acid sequence
consists essentially of a functionally operating region of an antibody variable
region including, without limitation, any naturally occurring or recombinant
form of such a molecule.

     1.7. "Licensed Antibody Phage Display Materials" means (i) any collection
or library of polynucleotide sequences, created by and under the exclusive
control of MORPHOSYS, which encodes at least one Immunoglobulin and which is
contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning
vectors capable of propagation in bacteria; (ii) any collection or library of
bacteriophage, created by or under the exclusive control of MORPHOSYS, wherein
an Immunoglobulin is (a) expressed as a fusion protein comprising an
Immunoglobulin or at least a functionally operating region of an antibody
variable region and an outer surface polypeptide, or a fragment thereof, of a
bacteriophage or (b) expressed separately and linked to an outer surface
polypeptide, or a fragment thereof, of a bacteriophage; or (iii) any material
required to generate any collection or library according to (i) and/or (ii),
each of which under (i), (ii) and/or (iii) infringe, but for the license granted
herein, the XOMA Patent Rights. For the avoidance of doubt, and without
expanding the definition thereof, specifically excluded from the definition of
Licensed Antibody Phage Display Materials are (x) any article of manufacture or
composition of matter suitable for display, expression or secretion of an
Immunoglobulin in or from any organism or system other than bacteria and (y) any
materials or composition of matter otherwise meeting the definition of Licensed
Antibody Phage Display Materials but created by or under the control of any
entity, other than MORPHOSYS, engaged in the licensing, manufacture, sale, offer
for sale, import or export of phage display services, products or materials;
provided, that, notwithstanding the foregoing, any materials or composition of
matter otherwise meeting the definition of Licensed Antibody Phage Display
Materials but created by or under the exclusive control of a

                                      -2-
<PAGE>

MORPHOSYS Collaborator shall constitute Licensed Antibody Phage Display
Materials, but only to the extent derived by such MORPHOSYS Collaborator
exclusively from Licensed Antibody Phage Display Materials created by or under
the exclusive control of MORPHOSYS and properly transferred by MORPHOSYS to such
MORPHOSYS Collaborator in accordance with the applicable provisions of this
Agreement and such MORPHOSYS Collaborator acknowledges that the transfer
restrictions and other provisions hereof apply thereto.

     1.8. "Licensed Immunoglobulin" means any Immunoglobulin discovered,
isolated or characterized by MORPHOSYS or a MORPHOSYS Collaborator (as defined
below) through the use of Licensed Antibody Phage Display Materials.

     1.9. "Licensed Immunoglobulin Information" means any data, know-how or
other information relating, concerning or pertaining to a Product, including,
without limitation, data, know-how or other information characterizing or
constituting such Licensed Immunoglobulin's polynucleotide or amino acid
sequence, purported function or utility, antigen binding affinity, or physical
or biochemical property.

     1.10. "MORPHOSYS Collaborator" means any person or entity (including a
corporation or an academic institution) who is an authorized end-user of
Licensed Antibody Phage Display Materials, the intended recipient of Products or
Licensed Immunoglobulin Information transferred from MORPHOSYS and/or a person
or entity on whose behalf MORPHOSYS knowingly engages in Antibody Phage Display;
provided, however, that such person or entity shall not be deemed to be a
MORPHOSYS Collaborator unless and until the requirements of Section 2.4 are
complied with. No person or entity shall be deemed to be a MORPHOSYS
Collaborator if such person or entity is engaged in the out-licensing,
commercial manufacture, sale, offer for sale, import for sale or export for sale
of immunoglobulin or antibody phage display services, immunoglobulin or antibody
phage display libraries, immunoglobulin or antibody phage display products or
immunoglobulin or antibody phage display materials, unless, pursuant to a
written agreement (other than this Agreement), executed after the Effective
Date, XOMA has granted to such person or entity a valid license or covenant not
to sue under the XOMA Patent Rights which explicitly extends to the activities
identified in this second to last sentence of Section 1.10. XOMA shall provide
MORPHOSYS prompt written notice of those written agreements or covenants not to
sue which satisfy the requirements of the prior sentence. No person or entity
may claim the status of MORPHOSYS Collaborator with respect to any acts or
activities which are unrelated to the use of Licensed Antibody Phage Display
Materials provided by MORPHOSYS.

     1.11. "Net Sales" means, in the case of the sale, either directly or
through a Third Party, of any Product by or on behalf of MORPHOSYS or any joint
venture or similar entity or arrangement in which MORPHOSYS is a participant (a
"MORPHOSYS Selling Entity"), the aggregate gross sales proceeds derived by
MORPHOSYS therefrom less (a) any sales or other taxes, assessments, charges or
fees imposed by any government authority which are paid, directly or indirectly,
by MORPHOSYS and (b) a discount from the gross sales proceeds to cover costs
associated with MORPHOSYS's sale of Product, as applicable, in respect of
transport, insurance premiums, returns, discounts, other miscellaneous costs and
expenses and rebates actually allowed and taken,

                                      -3-
<PAGE>

all determined in accordance with U.S. generally accepted accounting principles.
For the sake of clarity, it is understood that Net Sales does not include sales
of Products developed by or solely on behalf of MORPHOSYS or a MORPHOSYS
Collaborator unless sold by a MORPHOSYS Selling Entity. As used herein, "joint
venture" means a legal entity in the nature of a partnership engaged in a joint
undertaking for profit.

     1.12. "Product" means any composition of matter or article of manufacture,
including without limitation any diagnostic, prophylactic or therapeutic
product, which (a) contains a Licensed Immunoglobulin; or (b) was discovered or
created by or arose directly out of use of Licensed Antibody Phage Display
Materials or the conduct of Antibody Phage Display by MORPHOSYS or a MORPHOSYS
Collaborator.

     1.13. "Research and Development" means the identification, selection,
isolation, purification, characterization, study and/or testing and/or use of a
Product for any purpose, including, without limitation, the discovery and
development of human therapeutics or diagnostics. Included within the definition
of "Research and Development" shall be all in vitro screening or assays
customarily performed in pre-clinical and clinical research and uses associated
with obtaining FDA or equivalent agency regulatory approval. "Research and
Development" shall not include commercial or industrial manufacture or any
activities solely directed to the creation of such capacities.

     1.14. "Research Quantities" means those quantities of a Licensed
Immunoglobulin reasonably required for Research and Development purposes.

     1.15. "Third Party" means any person or entity other than MORPHOSYS or
XOMA.

     1.16. "Valid Claim" means (i) a claim of an issued and unexpired patent
included within the XOMA Patent Rights which has not been held invalid in a
final decision of a court of competent jurisdiction from which no appeal may be
taken, and which has not been disclaimed or admitted to be invalid or
unenforceable through reissue or otherwise, or (ii) a claim of a pending patent
application within the XOMA Patent Rights.

     1.17. "XOMA Patent Right(s)" means the patent applications and patents
listed on Schedule 1.17 hereto and, solely to the extent any Valid Claim would
cover or be included in the license grants provided for herein, all divisions,
continuations, continuations-in-part, applications claiming priority thereto,
and substitutions thereof; all foreign patent applications corresponding to the
preceding applications; all U.S. and foreign patents issuing on any of the
preceding applications, including extensions, reissues and re-examinations; and
any other patent rights owned by XOMA which XOMA has the right to license or
sublicense and which would be infringed by the activities of MORPHOSYS
contemplated hereunder but for this Agreement. XOMA Patent Rights shall also
include (i) any improvements of the foregoing that are owned or controlled by
XOMA and (ii) any patents or patent applications owned or controlled by XOMA
containing a claim that is dominating over the foregoing patent rights (i.e., is
necessarily infringed by the practicing of a claim in one of the foregoing
applications).

                                      -4-
<PAGE>

                                    ARTICLE 2

                            XOMA LICENSE TO MORPHOSYS

     2.1. Grants. Subject to the other terms and conditions of this Agreement,
XOMA hereby grants to MORPHOSYS a worldwide, non-exclusive, non-transferable
license (unless transferred under Section 8.2), without any right to sublicense,
under the XOMA Patent Rights to:

          (a) solely on its own behalf and on behalf of a MORPHOSYS
     Collaborator, make or have made Licensed Antibody Phage Display Materials;

          (b) solely on its own behalf and on behalf of a MORPHOSYS Collaborator
     and solely for Research and Development purposes, conduct Antibody Phage
     Display and use or have used Licensed Antibody Phage Display Materials and
     generate, use and have used Licensed Immunoglobulin Information;

          (c) solely on its own behalf and on behalf of a MORPHOSYS
     Collaborator, make or have made, use or have used, Research Quantities of a
     Licensed Immunoglobulin;

          (d) solely on its own behalf and on behalf of a MORPHOSYS
     Collaborator, transfer Antibody Phage Display Materials, Research
     Quantities of a Product or Licensed Immunoglobulin Information to a
     MORPHOSYS Collaborator;

          (e) solely on its own behalf and on behalf of a MORPHOSYS
     Collaborator, subject to the provisions of Section 2.3(b), make, have made,
     use, have used, sell, offer to sell, have offered for sale, import, have
     imported, export and have exported Products; and

          (f) solely on its own behalf, make or have made in commercial and/or
     industrial capacity, use, offer for sale, sell, import and export Products
     for use (i) in the treatment, prophylaxis, diagnosis or monitoring of a
     human disease state or condition or (ii) as research reagents. For the sake
     of clarity, the license granted in this Section 2.1(f) is personal to
     MORPHOSYS and is not to be used on behalf of any MORPHOSYS Collaborator or
     any other Third Party.

     2.2. Covenant Not To Sue. (a) XOMA covenants that it shall not assert, nor
shall it permit any third party that obtains a right to enforce the XOMA Patent
Rights to assert, a claim of infringement under the XOMA Patent Rights against
MORPHOSYS, any MORPHOSYS Collaborator or any other entity subject to Section
2.4(c) solely to the extent reasonably necessary to permit the authorized use of
Licensed Antibody Phage Display Materials, Products or Licensed Immunoglobulin
Information for activities or in a manner otherwise permitted under the
provisions of this Agreement. The covenant not to sue provided by this Section
2.2:

                                      -5-
<PAGE>

          (i) shall not extend to infringement of the XOMA Patent Rights arising
     out of making or the means or methods used to make any amount of a Licensed
     Immunoglobulin or Product other than Research Quantities (except as
     authorized by Section 2.1(f));

          (ii) may be terminated by XOMA in accordance with Article 7 as to any
     entity or person who has failed to materially discharge or comply with any
     applicable term of a written agreement between MORPHOSYS and a MORPHOSYS
     Collaborator provided for in Section 2.4; provided, that any such
     termination shall be retroactive to the date of the first notice of such
     failure given by MORPHOSYS to such entity or person (giving effect to any
     subsequent cure of such failure);

          (iii) is personal to MORPHOSYS or, as applicable, the MORPHOSYS
     Collaborator or other entity subject to Section 2.4(c), and, except as
     provided for by Section 8.2, cannot be assigned or transferred; and

          (iv) does not constitute a release or waiver of past, present or
     future infringement of the XOMA Patent Rights by MORPHOSYS or any Third
     Party, including, without limitation, any MORPHOSYS Collaborator acting
     outside of the scope of the written agreement with MORPHOSYS provided for
     in Section 2.4.

     (b) In addition to, but without limiting, the covenant not to sue provided
by Section 2.2(a), XOMA hereby grants to Schering AG a non-exclusive and
non-transferable license under the XOMA Patent Rights identical to, and limited
by the scope of, the covenant not to sue contained in Sections 2.2(a) (the
"Direct License"). Solely to the extent its activities are otherwise authorized
as those of a MORPHOSYS Collaborator under the applicable terms of this
Agreement, the Direct License permits Schering AG to enjoy the benefits of the
covenant not to sue granted under Section 2.2(a) as if it were a direct licensee
under the XOMA Patent Rights, provided, however, that the Direct License does
not constitute an independent or free standing grant of a license and is
expressly subject to and contingent upon the applicability of and compliance
with the other provisions of this Agreement. The Direct License shall not be
effective unless and until Schering AG delivers to XOMA a document, directly
enforceable by XOMA, pursuant to which Schering AG (a) represents and warrants
that it does and shall continue to meet the definition of MORPHOSYS
Collaborator; and (b) agrees that it shall abide by the relevant limitations and
obligations otherwise imposed upon MORPHOSYS Collaborators under this Agreement.
The Direct License shall survive only as long as this Agreement remains in force
and as to Schering AG has not been terminated.

     2.3. No Implied Rights. Only the rights and licenses granted pursuant to
the express terms of this Agreement shall be of any legal force or effect. No
license or other rights shall be deemed to have been granted to MORPHOSYS or a
MORPHOSYS Collaborator other than as expressly provided for in this Agreement.
MORPHOSYS renounces and hereby quitclaims any implied rights to licenses under
the XOMA Patent Rights that may arise by operation of this Agreement or under
applicable law. For the avoidance of doubt, the grants of rights made pursuant
to Sections 2.1 and 2.2 do not include, and expressly exclude, the following:

                                      -6-
<PAGE>

          (a) any right or license to engage in any activities on behalf of or
     in collaboration with any Third Party, other than a MORPHOSYS Collaborator;

          (b) any right or license to make or have made any amount (other than
     Research Quantities or except as authorized under Section 2.1(f)) of a
     Licensed Immunoglobulin or Product by practicing the XOMA Patent Rights;
     provided, however, that MORPHOSYS or, as applicable, a MORPHOSYS
     Collaborator shall be permitted to make or have made any Product by any
     means of its selection other than those which otherwise infringe a Valid
     Claim of the XOMA Patent Rights; and/or

          (c) any right to release any Third Party, including a MORPHOSYS
     Collaborator, from any claim of infringement under the XOMA Patent Rights.

Without limiting the foregoing, the parties acknowledge that nothing herein
shall be deemed to impose on MORPHOSYS any obligation to provide consideration
for, or grant MORPHOSYS any access or other rights to, any know-how of XOMA.

     2.4. Transfer Restrictions. (a) MORPHOSYS shall not (i) undertake any
Antibody Phage Display Activities on behalf of a Third Party or (ii) Dispose of
Licensed Antibody Phage Display Materials, a Licensed Immunoglobulin, Licensed
Immunoglobulin Information or the product of the practice of any method within
the scope of the XOMA Patents ("Transferred Materials") to any Third Party until
(in the case of either clause (i) or clause (ii)) such time as it has provided
to such Third Party the redacted copy of this Agreement referred to in Section
4.2 and the form of notice set out at Schedule 2.4.

     (b) If MORPHOSYS enters into a written arrangement with any Third Party
arising out of or relating to activities as to which it or such Third Party does
or intends to claim the benefits of any of the licenses or other grants provided
for by this Agreement, such written arrangement shall contain provisions (i)
pursuant to which the recipient of any Transferred Materials agrees to abide by
each of the limitations, restrictions and other obligations provided for by this
Agreement, including, without limitation, the restrictions on use of Transferred
Materials for purposes other than Research and Development; (ii) implementing a
covenant not to use Transferred Materials for any purpose other than for
Research and Development purposes otherwise authorized by this Agreement; (iii)
providing that the "first sale" doctrine does not apply to any Disposition; and
(iv) permitting a MORPHOSYS Collaborator to further Dispose of Transferred
Materials only to a Third Party who otherwise meets the definition of a
MORPHOSYS Collaborator and who executes a written agreement in which it
undertakes all of the obligations applied to the transferring party. XOMA shall
be, and the agreements subject to this Section 2.4 shall provide that XOMA shall
be, an intended third party beneficiary with respect to the foregoing
provisions.

     (c) The restrictions set forth in Sections 2.4(a)(ii) and 2.4(b)(iv) shall
not apply to any Disposition of Products, Licensed Immunoglobulins or Licensed
Immunoglobulin Information by MORPHOSYS or a MORPHOSYS Collaborator to a Third
Party, a MORPHOSYS Selling Entity or any joint venture or similar entity or
arrangement in which such MORPHOSYS Collabora-

                                      -7-
<PAGE>

tor is a participant (each a "Directed Third Party"), where such Directed Third
Party (i) performs services or conducts activities which are otherwise
authorized under this Agreement and which are solely for the benefit of
MORPHOSYS or such MORPHOSYS Collaborator and/or (ii) does not require and does
not claim the benefit of the licenses or covenant not to sue granted by XOMA
under this Agreement, provided, however, that MORPHOSYS and any such MORPHOSYS
Collaborator shall be responsible for ensuring compliance by any such Directed
Third Party with all applicable terms of this Agreement. For the sake of
clarity, nothing in this Section 2.4(c) shall constitute the grant of any rights
or licenses under the XOMA Patent Rights to any Directed Third Party.

     2.5. Reports, Records and Audits. (a) Thirty (30) days after the end of
each calendar quarter, commencing with the first calendar quarter commencing
after the Effective Date, MORPHOSYS shall deliver to XOMA a written report which
shall specify the name, address and contact person for each and every MORPHOSYS
Collaborator and any person or entity receiving Licensed Antibody Phage Display
Materials or a Licensed Immunoglobulin.

     (b) Thirty (30) days after the end of each calendar year, commencing with
the first calendar year to commence after the Effective Date, MORPHOSYS shall
deliver to XOMA a written report which shall summarize with reasonable
particularity the current status of activities or compositions of matter as to
which MORPHOSYS claims the right of license hereunder.

     (c) MORPHOSYS shall maintain records fully and properly reflecting those
activities covered by this Agreement (including, without limitation, work done
with the Licensed Antibody Phage Display Materials) and/or to be reported to
XOMA pursuant to Section 2.5(a) and (b) (the "Records"), in sufficient detail
and in good scientific manner appropriate for patent, regulatory and
manufacturing purposes for at least three (3) years. Upon the written request of
XOMA and not more than once in each calendar year, MORPHOSYS shall permit an
independent consultant appointed by XOMA, at XOMA's expense, to have access
during normal business hours to such of the records of MORPHOSYS as may be
reasonably necessary to verify compliance with the terms of this Agreement, as
well as the accuracy of the reports hereunder. MORPHOSYS shall certify any
statements by MORPHOSYS personnel as to their accuracy and correctness. The
consultant shall not be permitted to see or receive any specific information
concerning targets or antibodies of either MORPHOSYS or any of its collaborators
and shall disclose to XOMA only the results and conclusions of its review and
the specific details concerning any discrepancies. No other information shall be
shared by the consultant without the prior consent of MORPHOSYS unless
disclosure is required by law, regulation or judicial order.

     2.6. Ownership; Enforcement. At all times XOMA will retain ownership of the
XOMA Patent Rights and may use and commercialize such XOMA Patent Rights itself
or with any Third Party. XOMA retains the right, at its sole discretion, to
enforce, maintain and otherwise protect the XOMA Patent Rights. MORPHOSYS will
reasonably cooperate with XOMA, at XOMA's expense, with respect to any actions
XOMA may choose to take related to the enforcement, maintenance or protection of
the XOMA Patent Rights.

                                      -8-
<PAGE>

     2.7. Oppositions and/or Appeals to Oppositions. MORPHOSYS hereby agrees not
to enter into any opposition to and/or appeal from any decision by the patent
authorities of any country on the XOMA Patent Rights and shall not assist or
otherwise cooperate with another party in any such opposition or appeal.

     2.8. Release From Past Infringement. XOMA releases MORPHOSYS from any
claims, demands, and rights of action arising out of and/or based upon any act
or omission committed by MORPHOSYS prior to the Effective Date, including,
without limitation, claims of infringement under the XOMA Patent Rights (the
"Release") and XOMA releases each Third Party identified on Schedule 2.8 as a
party on or prior to the Effective Date to an agreement set forth thereon from
any claims, demands, and rights of action arising out of and based upon any
infringement of the XOMA Patent Rights (the "Third Party Release"); provided,
however, that the Release and Third Party Release provided for in this Section
2.8 shall extend only to claims, demands or rights of action existing as of the
Effective Date and which arose solely out of those activities conducted pursuant
to and in accordance with the agreements set forth on Schedule 2.8 as in effect
on the Effective Date. Nothing in this Section 2.8 shall be deemed to be a
release of any claim, demand or right of action XOMA may now or in the future
have against Affitech AS, BioInvent Therapeutic AB, Biosite Incorporated,
Cambridge Antibody Technology Limited, Crucell N.V., Dyax Corporation or any
entity or person engaged in the out-licensing, commercial manufacture, sale,
offer for sale, import for sale or export for sale of immunoglobulin or antibody
phage display services, immunoglobulin or antibody phage display libraries,
immunoglobulin or antibody phage display products or immunoglobulin or antibody
phage display materials or any of their collaborators. For the sake of clarity,
if any Third Party identified on Schedule 2.8 as a party on the Effective Date
to an agreement set forth thereon has also collaborated with any other entity or
person engaged in the out-licensing, commercial manufacture, sale, offer for
sale, import for sale or export for sale of immunoglobulin or antibody phage
display services, immunoglobulin or antibody phage display libraries,
immunoglobulin or antibody phage display products or immunoglobulin or antibody
phage display materials, including but not limited to those entities referred to
in the immediately preceding sentence, then the release herein shall extend
solely to the activities of such Third Party that are carried out pursuant to
and in accordance with the agreement set forth on Schedule 2.8 to which it is a
party as in effect on the Effective Date. The Release and the Third Party
Release shall become irrevocable only upon receipt by XOMA of payment in full by
MORPHOSYS of the amounts set forth in Section 3.1 and 3.3 and shall be revoked
in their entirety and null and void ab initio, immediately and without further
action of the parties, in the event such payment in full by MORPHOSYS is not
received by XOMA on or prior to October 1, 2002, regardless of any payment
received thereafter.

                                      -9-
<PAGE>

                                    ARTICLE 3

                                    PAYMENTS

     3.1. License Fee. In consideration for XOMA's execution of this Agreement,
MORPHOSYS shall pay XOMA a one time, non-refundable license fee of Four Million
United States Dollars (US$4,000,000), which shall be considered as a fee for
license from the Effective Date forward. This license fee shall be paid in one
payment to XOMA and in no event later than October 1, 2002, provided that
MORPHOSYS agrees to use commercially reasonable efforts to make such payment as
soon as reasonably practicable.

     3.2. Shares. (a) In full substitution for the payment obligations of
MORPHOSYS pursuant to Section 3.1, MorphoSys may, until September 30, 2002,
elect in its sole discretion to issue and transfer newly created MorphoSys
shares ("New Shares") to XOMA by using its authorized capital against
contribution of the license granted in Section 2.1 of this Agreement (capital
increase against contribution in kind). In this case, the Management Board
(Vorstand) of MORPHOSYS will, with the approval of the Supervisory Board
(Aufsichtsrat) of MORPHOSYS, resolve to issue the New Shares while excluding
pre-emptive rights (the date of such resolution by the Management Board of
MORPHOSYS, "Resolution Date"). The number of New Shares shall be calculated as
follows:

         US$4,800,000 converted into Euro according to the Exchange Rate
         ---------------------------------------------------------------
                              Relevant Share Price

     ; where,

     Exchange Rate is the US$/Euro exchange rate published by Bloomberg one day
     prior to the Resolution Date;

     Relevant Share Price is the price of MORPHOSYS shares traded on the Neuer
     Markt stock exchange as fixed in the Xetra afternoon auction (Xetra
     Nachmittagsauktion) one day prior to the Resolution Date; and

     fractions of shares shall not be taken into account.

MORPHOSYS shall promptly notify XOMA of its election to issue New Shares. To the
extent possible, MORPHOSYS will notify XOMA in advance of such decision.
Subsequent to the resolution of the Management Board of MORPHOSYS to issue the
New Shares, XOMA shall subscribe to the New Shares by executing a subscription
certificate (Zeichnungsschein) in form and substance as attached hereto in
Schedule 3.2.1. Pursuant to Sections 203,189 German Stock Corporation Act
(AktG), the New Shares will come into existence upon registration with the
Commer-

                                      -10-
<PAGE>

cial Register. MORPHOSYS shall obtain such registration with the Commercial
Register of Munich and shall obtain admission for trading of the New Shares at
the Neuer Markt stock exchange as soon as reasonably practicable. XOMA shall use
commercially reasonable efforts to take all necessary steps and render all
declarations necessary and appropriate to implement the transactions as
described in this subparagraph.

     (b) MORPHOSYS may, until September 30, 2002, elect to pay the license fee
in part in cash (this cash component, the "Cash Component") and in part in New
Shares. In this case, Section 3.1 shall apply with respect to the payment of the
Cash Component and this Section 3.2 shall apply with respect to the payment in
New Shares; provided that the number of New Shares shall be calculated as
follows:

               (US$4,800,000 converted into Euro according to the
                        Exchange Rate - Cash Component)
               --------------------------------------------------
                              Relevant Share Price

     ; where,

     Exchange Rate is the US$/Euro exchange rate published by Bloomberg one day
     prior to the Resolution Date;

     Relevant Share Price is the price of MORPHOSYS shares traded on the Neuer
     Markt stock exchange as fixed in the Xetra afternoon auction (Xetra
     Nachmittagsauktion) one day prior to the Resolution Date; and

     fractions of shares shall not be taken into account.

     (c) Attached hereto as Schedule 3.2.2 is a legal opinion of counsel of
MorphoSys delivered to XOMA as of the date of this Agreement. If MorphoSys
elects to pay the license fee in full or in part in New Shares pursuant to this
Section 3.2, MORPHOSYS shall, upon registration of the New Shares with the
Commercial Register, provide XOMA with an additional legal opinion of counsel of
MORPHOSYS in form and substance as attached hereto in Schedule 3.2.3.

     3.3. Release Payment. In consideration for the release provided by Section
2.8, MORPHOSYS shall pay XOMA a one time, non-refundable payment of One Million
United States Dollars (US$1,000,000), which shall be applied retroactively as a
fee for license from the first infringing use by MORPHOSYS through the Effective
Date. This payment shall be paid within thirty (30) days of the receipt of a
fully executed copy of the Agreement.

                                      -11-
<PAGE>

     3.4. Milestones. Upon achievement of the following milestones with respect
to each Product, MORPHOSYS shall pay XOMA the applicable milestone payments
below:

--------------------------------------------------------------------------------
Event                                                      Payment
--------------------------------------------------------------------------------

Filing of an investigational new drug application or       US$100,000
equivalent
--------------------------------------------------------------------------------
First receipt of authorization or clearance to market      US$250,000
--------------------------------------------------------------------------------

For the sake of clarity, it is understood that the foregoing milestone payments
shall only be due with respect to any Product developed by or on behalf of
MORPHOSYS or any joint venture or similar entity or arrangement in which
MORPHOSYS is a participant.

     3.5. Royalties. During the term of this Agreement, MORPHOSYS shall pay to
XOMA a royalty in cash equal to [*] percent ([*] %) of the Net Sales of any
Product(s) in each calendar quarter, commencing with the first calendar quarter
ending after the Effective Date. Royalties due under this Article 3 shall be
payable on a country-by-country and Product-by-Product basis from the first
commercial sale of such Product until the expiration of the last-to-expire XOMA
Patent Right in such country with respect to which a Valid Claim covers the
manufacture, use, sale, offer for sale, import or export of such Product.

     3.6. Commercially Reasonable Efforts. MORPHOSYS shall use commercially
reasonable efforts to collect or receive any payments or other consideration due
to it relating to any activities that would give rise to an obligation under
Section 3.5.

     3.7. Payments; Currency. All payments due hereunder shall be paid by wire
transfer in United States dollars in immediately available funds to an account
designated by XOMA. Payments required pursuant to Section 3.4 hereof shall be
due and payable to XOMA when the corresponding milestone is achieved and shall
be paid within thirty (30) days thereof. Payments required pursuant to Section
3.5 hereof shall be due and payable to XOMA when the corresponding Net Sales are
recorded by MORPHOSYS (or any joint venture or similar entity in which MORPHOSYS
is a participant) and shall be paid within thirty (30) days of the end of each
calendar quarter. If any currency conversion shall be required in connection
with the payment of any royalties hereunder, such conversion shall be made by
using the exchange rate for the purchase of U.S. dollars quoted in the U.S.
version of the Wall Street Journal on the last business day of the calendar
quarter to which such payments relate.

     3.8. Payment Reports. MORPHOSYS shall make a written report to XOMA within
thirty (30) days of the achievement of each of the milestones set forth in
Section 3.4 with respect to each Product, stating in each such report the
Product to which such milestone relates and the specific milestone achieved,
including the relevant agency or other regulatory body. After the first
commercial sale of a Product on which royalties are required to be paid
hereunder, MORPHOSYS shall make quarterly written reports to XOMA within sixty
(60) days after the end of each calendar

                                      -12-
<PAGE>

quarter, stating in each such report, by country, the number, description, and
aggregate Net Sales of each Product sold during the calendar quarter. XOMA shall
treat all such reports as Confidential Information of MORPHOSYS. Concurrently
with the making of such reports, MORPHOSYS shall pay XOMA the amounts specified
in Sections 3.4 and 3.5 hereof.

     3.9. Payment Records and Inspection. MORPHOSYS shall keep complete, true
and accurate books of account and records for the purpose of determining the
amounts payable under this Agreement. Such books and records shall be kept at
the principal place of business of MORPHOSYS for at least three (3) years
following the end of the calendar quarter to which they pertain. Upon the
written request of XOMA and not more than once in each calendar year, MORPHOSYS
shall permit an independent certified public accounting firm of internationally
recognized standing selected by XOMA and reasonably acceptable to MORPHOSYS, at
XOMA's expense, to have access during normal business hours to such of the
records of MORPHOSYS as may be reasonably necessary to verify the accuracy of
the royalty reports hereunder for any year ending not more than thirty-six (36)
months prior to the date of such request. The accounting firm shall disclose to
XOMA only the results and conclusions of its review and the specific details
concerning any discrepancies. No other information shall be shared by the
accounting firm without the prior consent of MORPHOSYS unless disclosure is
required by law, regulation or judicial order. Inspections conducted under this
Section 3.9 shall be at the expense of XOMA, unless an underpayment exceeding
two percent (2%) of the amount stated for the full period covered by the
inspection is identified, in which case all out-of-pocket costs relating to the
inspection will be paid immediately by MORPHOSYS. Any underpayments or unpaid
amounts discovered by such inspections or otherwise will be paid immediately by
MORPHOSYS, with interest from the date(s) such amount(s) were due at a rate of
one and one-half percent (1.5%) per month from the due date until paid in full.

     3.10. No Admissions. The parties acknowledge and affirm that, as to any
Third Party, the allocation of amounts set forth in Article 3 of this Agreement
does not constitute an admission by either party either as to the damages
actually suffered by XOMA with respect to any past infringement of the XOMA
Patent Rights or respecting the calculation of a reasonable royalty by any court
or trier of fact.

                                    ARTICLE 4

                                 CONFIDENTIALITY

     4.1. Confidential Information. Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for ten (10) years
thereafter, the receiving party shall keep completely confidential and shall not
publish or otherwise disclose and shall not use for any purpose except for the
purposes contemplated by this Agreement any Confidential Information furnished
to it by the disclosing party hereto, except to the extent that it can be
established by the receiving party by written proof that such Confidential
Information:

                                      -13-
<PAGE>

          (a) was already known to the receiving party, other than under an
     obligation of confidentiality, at the time of disclosure;

          (b) was generally available to the public or otherwise part of the
     public domain at the time of its disclosure to the receiving party;

          (c) became generally available to the public or otherwise part of the
     public domain after its disclosure other than through any act or omission
     of the receiving party in breach of this Agreement; or

          (d) was subsequently lawfully disclosed to the receiving party by a
     person other than a party hereto.

     4.2. Permitted Use and Disclosures. Each party hereto may use or disclose
information disclosed to it by the other party to the extent such use or
disclosure is reasonably necessary in complying with applicable law or
government regulations or conducting clinical trials; provided, however, that if
a party is required to make any such disclosure of another party's Confidential
Information, other than pursuant to a confidentiality agreement, it will give
reasonable advance notice to the latter party of such disclosure and, will use
its reasonable efforts to secure confidential treatment of such information
prior to its disclosure (whether through protective orders or otherwise).
Attached hereto as Schedule 4.2 is a redacted copy of this Agreement which
MORPHOSYS shall be free, without obtaining any consent from XOMA, to provide to
Third Parties who indicate an interest in becoming a MORPHOSYS Collaborator. In
addition, MORPHOSYS shall be free, without obtaining any consent from XOMA, to
provide to Third Parties who indicate an interest in becoming a MORPHOSYS
Collaborator an oral summary of the provisions of Section 2.4(c) hereof and to
provide the text thereof to Third Parties who actually become MORPHOSYS
Collaborators.

     4.3. Confidential Terms. Except as expressly provided herein, MORPHOSYS
agrees not to disclose any terms of this Agreement to any Third Party without
the consent of XOMA; provided, that disclosures may be made as required by
securities or other applicable laws, or to a party's accountants, attorneys and
other professional advisors.

     4.4. Agreement Announcement. The parties hereby agree to the release of a
press release in the form attached hereto as Schedule 4.4 upon full execution of
this Agreement and that the consummation of this Agreement, as well as such
terms as are expressly described in such press release, shall be deemed to be in
the public domain.

                                      -14-
<PAGE>

                                    ARTICLE 5

                      REPRESENTATIONS AND WARRANTIES, ETC.

     5.1. Representations and Warranties. (a) XOMA represents and warrants to
MORPHOSYS that: (i) it is the sole and exclusive owner or exclusive licensee of
all right, title and interest in the XOMA Patent Rights; (ii) XOMA has the legal
right, authority and power to enter into this Agreement; (iii) this Agreement
shall constitute a valid and binding obligation of XOMA enforceable in
accordance with its terms; and (iv) the performance of obligations under this
Agreement by XOMA shall not result in a breach of any agreements, contracts or
other arrangements to which it is a party.

     (b) MORPHOSYS represents and warrants to XOMA that: (i) MORPHOSYS has the
legal right, authority and power to enter into this Agreement; (ii) this
Agreement shall constitute a valid and binding obligation of MORPHOSYS
enforceable in accordance with its terms; and (iii) the performance of
obligations under this Agreement by MORPHOSYS will not result in a breach of any
agreements, contracts or other arrangements to which it is a party.

     5.2. Disclaimer. Nothing in this Agreement is or shall be construed as:

          (a) A warranty or representation by XOMA as to the validity or scope
     of any claim or patent within the XOMA Patent Rights;

          (b) A warranty or representation that anything made, used, sold, or
     otherwise disposed of under any license granted in this Agreement is or
     will be free from infringement of any patent rights or other intellectual
     property right of any Third Party;

          (c) An obligation to bring or prosecute actions or suits against Third
     Parties for infringement of any of the XOMA Patent Rights; or

          (d) Granting by implication, estoppel, or otherwise any licenses or
     rights under patents or other rights of XOMA, MORPHOSYS or Third Parties,
     regardless of whether such patents or other rights are dominant or
     subordinate to any patent within the XOMA Patent Rights.

     5.3. No Other Warranties. EXCEPT AS OTHERWISE SET FORTH IN SECTION 5.1
ABOVE, XOMA MAKES NO WARRANTIES WITH RESPECT TO ANY OF THE PATENT RIGHTS
LICENSED HEREUNDER, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW,
BY STATUTE OR OTHERWISE, AND XOMA SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF SUCH
PATENT RIGHTS OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY
THIRD PARTY.

                                      -15-
<PAGE>

     5.4. Certain Agreements. MORPHOSYS represents and warrants that it has in
its possession, and agrees that throughout the term of this Agreement and for a
period of three (3) years thereafter it will maintain in an accessible location,
true, complete and legible copies of each of the agreements set forth on
Schedule 2.8 as in effect on the Effective Date, including all schedules,
exhibits and other similar documents necessary for the correct interpretation of
the provisions thereof.

                                    ARTICLE 6

                                 INDEMNIFICATION

     6.1. Indemnification. (a) MORPHOSYS agrees to indemnify, defend and hold
XOMA and its directors, officers, employees and agents (the "Indemnified
Parties" and each, an "Indemnified Party") harmless from and against any and all
liabilities, losses and expenses (including, without limitation, attorneys and
professional fees and other costs of litigation), resulting from any claims,
demands or causes of action by any party other than MORPHOSYS (each, a
"Liability") arising out of (i) the possession, manufacture, use, sale or other
disposition of Product, Antibody Phage Display Materials, Licensed
Immunoglobulin or the provisions of any service or goods relating thereto by
MORPHOSYS or any customer, vendor or other representative of MORPHOSYS, whether
based on breach of warranty, negligence, product liability or otherwise, (ii)
the exercise of any right granted to MORPHOSYS pursuant to this Agreement or
(iii) any claim by Biosite Incorporated, as set forth below in Section 6.1(b),
except to the extent, in each case, that such Liability is caused by the gross
negligence or willful misconduct of XOMA.

     (b) Notwithstanding any other provision of this Agreement, any
indemnification of XOMA by MORPHOSYS for any claim by Biosite shall only arise
in the event that MORPHOSYS brings a claim against Biosite for damages arising
out of Biosite's license with MORPHOSYS, effective January 1, 2000, and as a
result Biosite then brings a claim against XOMA for damages. MORPHOSYS's
liability under this Section 6.1(b) shall be limited to reasonable attorneys'
fees (in the event that MORPHOSYS does not assume the defense under Section
6.2(c)) and the actual amounts paid to Biosite attributable to MORPHOSYS's claim
against Biosite. MORPHOSYS'S INDEMNIFICATION UNDER THIS SECTION 6.1(B) SHALL NOT
INCLUDE ANY INCIDENTAL AND CONSEQUENTIAL DAMAGES SUFFERED BY XOMA. MORPHOSYS
EXPRESSLY DISCLAIMS ALL OTHER INDEMNIFICATION, EXPRESS OR IMPLIED, ON EITHER
LEGAL OR EQUITABLE GROUNDS AS TO THE SUBJECT MATTER OF THIS SECTION 6.1(B).

     6.2. Procedure. To receive the benefit of indemnification under Section
6.1, an Indemnified Party must (a) promptly notify MORPHOSYS in writing of a
claim or suit; provided, that failure to give such notice shall not relieve
MORPHOSYS of its indemnification obligations except where, and solely to the
extent that, such failure actually and materially prejudices the rights of
MORPHOSYS); (b) provide reasonable cooperation (at MORPHOSYS's expense); and (c)
ten-

                                      -16-
<PAGE>

der to MORPHOSYS (and its insurer) full authority to defend or settle the claim
or suit; provided that no settlement requiring any admission by the Indemnified
Party or that imposes any obligation on the Indemnified Party shall be made
without the Indemnified Party's consent; and, provided, further that nothing
herein shall be deemed to give MORPHOSYS any right to control any proceeding
involving the XOMA Patent Rights or any claim XOMA may bring against any Third
Party. MORPHOSYS shall not have any obligation of indemnification in connection
with any settlement made without MORPHOSYS's written consent. The Indemnified
Party has the right to participate at its own expense in the claim or suit and
in selecting counsel therefor. The Indemnified Party shall cooperate with
MORPHOSYS (and its insurer), as reasonably requested.

                                    ARTICLE 7

                              TERM AND TERMINATION

     7.1. Term. Subject to Sections 7.5 and 7.6 hereof, the term of this
Agreement will commence on the Effective Date and remain in full force and
effect until the expiration of the last patent within the XOMA Patent Rights,
unless earlier terminated pursuant to Sections 7.2 or 7.3.

     7.2. Termination Event. This Agreement may be terminated by either Party
upon any material breach by the other Party of any material obligation or
condition of the Agreement, effective fifteen (15) days after giving notice to
the breaching party of such termination in the case of a payment breach and
sixty (60) days after giving written notice to the breaching Party of such
termination in the case of any other breach, which notice shall describe such
breach in reasonable detail. The foregoing notwithstanding, if such breach is
cured or shown to be non-existent within the aforesaid fifteen (15) or sixty
(60) day period, the notice shall be deemed automatically withdrawn and of no
effect and the notifying Party shall provide written notice to the breaching
Party of the withdrawal.

     7.3. Termination for Insolvency. If voluntary or involuntary proceedings by
or against MORPHOSYS are instituted in bankruptcy under any insolvency law, or a
receiver or custodian is appointed for MORPHOSYS, or proceedings are instituted
by or against MORPHOSYS for corporate reorganization or the dissolution of
MORPHOSYS, which proceedings, if involuntary, shall not have been dismissed
within sixty (60) days after the date of filing, or if MORPHOSYS makes an
assignment for the benefit of creditors, or substantially all of the assets of
MORPHOSYS are seized or attached and not released within sixty (60) days
thereafter, XOMA may immediately terminate this Agreement effective upon notice
of such termination.

     7.4. Effect of Termination. (a) Termination of this Agreement shall not
release any party hereto from any liability which, at the time of such
termination, has already accrued to the other party or which is attributable to
a period prior to such termination nor preclude either party from pursuing any
rights and remedies it may have hereunder or at law or in equity with respect to
any breach of this Agreement. It is understood and agreed that monetary damages
may not be a

                                      -17-
<PAGE>

sufficient remedy for any breach of this Agreement and that the non-breaching
party may be entitled to injunctive relief as a remedy for any such breach. Such
remedy shall not be deemed to be the exclusive remedy for any such breach of
this Agreement, but shall be in addition to all other remedies available at law
or in equity.

     (b) Upon any termination of this Agreement, MORPHOSYS and XOMA shall
promptly return to the other party all Confidential Information received from
the other party (except that each party may retain one copy for its files solely
for the purpose of determining its rights and obligations hereunder).

     (c) All licenses granted under Article 2 hereof shall terminate and be of
no further effect upon the termination of this Agreement; provided, however,
that any MORPHOSYS Collaborator that is the beneficiary of certain rights under
this Agreement shall maintain such rights, notwithstanding the termination of
this Agreement, provided that such MORPHOSYS Collaborator complies with the
applicable provisions of this Agreement.

     7.5. Survival. Sections 2.5, 2.6, 2.7, 3.4, 3.5, 3.7, 3.8, 3.9, 3.10, 7.4
and 7.5, and Articles 4, 5, 6 and 8 of this Agreement shall survive any
termination hereof.

     7.6. Contested Validity. If MORPHOSYS or a MORPHOSYS Collaborator knowingly
contests, directs another to contest or assists another in contesting the
validity or enforceability of any of the XOMA Patent Rights licensed hereunder,
XOMA shall have the right to terminate all of the rights and licenses hereby
granted to MORPHOSYS and any MORPHOSYS Collaborator under the XOMA Patent
Rights; provided, however, that in the event a MORPHOSYS Collaborator knowingly
contests, directs another to contest or assists another in contesting the
validity or enforceability of any of the XOMA Patent Rights licensed hereunder
other than at the direction, and without the knowing assistance or other
involvement (other than as required by law or court order), of MORPHOSYS, then
the foregoing termination right of XOMA shall apply only to the rights hereby
granted to such MORPHOSYS Collaborator.

                                    ARTICLE 8

                            MISCELLANEOUS PROVISIONS

     8.1. Governing Laws. This Agreement and any dispute, including without
limitation any arbitration, arising from the performance or breach hereof shall
be governed by and construed and enforced in accordance with the laws of the
state of California, without reference to conflicts of laws principles.

     8.2. Assignment. Neither party may transfer or assign this Agreement,
directly or indirectly, or any of its rights hereunder, other than to one or
more Affiliates and other than to a successor of XOMA Ltd. under a Change in
Control of XOMA Ltd. or to a successor of MorphoSys AG under a Change in Control
of MorphoSys AG to which Section 8.3 does not apply, without the

                                      -18-
<PAGE>

prior written consent of the other party. Any such attempted transfer or
assignment in violation of this Section 8.2 shall be void; provided, that in the
event of a permitted Change in Control, the original party's (or its
successor's) obligations hereunder shall continue. This Agreement shall be
binding upon and inure to the benefit of the parties and their permitted
successors and assigns.

     8.3. Certain Changes in Control. Notwithstanding any other provision of
this Agreement to the contrary, this Agreement shall automatically terminate,
without further action by the parties, in the event of (a) a transaction or
series of related transactions in which Affitech AS, BioInvent Therapeutic AB,
Biosite Incorporated, Cambridge Antibody Technology Limited, Crucell N.V., Dyax
Corporation or any entity or person whose principal business is, or who has a
substantial business in, the out-licensing, commercial manufacture, sale, offer
for sale, import for sale or export for sale of immunoglobulin or antibody phage
display services, immunoglobulin or antibody phage display libraries,
immunoglobulin or antibody phage display products or immunoglobulin or antibody
phage display materials is a party and which results in a Change in Control of
MORPHOSYS, or (b) a transaction or series of related transactions in which
MORPHOSYS is a party and which results in a Change in Control of a person or
entity described in clause (a) above.

     8.4. Waiver. No waiver of any rights shall be effective unless consented to
in writing by the party to be charged and the waiver of any breach or default
shall not constitute a waiver of any other right hereunder or any subsequent
breach or default.

     8.5. Severability. In the event that any provisions of this Agreement are
determined to be invalid or unenforceable by a court of competent jurisdiction,
the remainder of the Agreement shall remain in full force and effect without
said provision.

     8.6. Notices. All notices, requests and other communications hereunder
shall be in writing and shall be delivered or sent in each case to the
respective address specified below, or such other address as may be specified in
writing to the other party hereto, and shall be effective on receipt:

         MORPHOSYS:                 MorphoSys AG
                                    Lena-Christ-Str. 48
                                    82152 Martinsried/Planegg
                                    Germany
                                    Attn:  General Counsel

         with a copy (which shall not constitute notice) to:

                                    MorphoSys USA, Inc.
                                    5605 Carnegie Blvd., Suite 275
                                    Charlotte, NC  28209
                                    U.S.A.
                                    Attn:  President

                                      -19-
<PAGE>

         XOMA:                      XOMA Ireland Limited
                                    Shannon Airport House
                                    Shannon, County Clare
                                    Ireland
                                    Attn:  Company Secretary

         with a copy (which shall not constitute notice) to:

                                    XOMA (US) LLC
                                    2910 Seventh Street
                                    Berkeley, CA  94710
                                    U.S.A.
                                    Attn:  Company Secretary

     8.7. Independent Contractors. Both parties are independent contractors
under this Agreement. Nothing contained in this Agreement is intended nor is to
be construed so as to constitute XOMA or MORPHOSYS as partners or joint
venturers with respect to this Agreement. Except as expressly provided herein,
neither party shall have any express or implied right or authority to assume or
create any obligations on behalf of or in the name of the other party or to bind
the other party to any other contract, agreement, or undertaking with any third
party.

     8.8. Compliance with Laws. In exercising their rights under this license,
the parties shall comply in all material respects with the requirements of any
and all applicable laws, regulations, rules and orders of any governmental body
having jurisdiction over the exercise of rights under this Agreement. MORPHOSYS
shall be responsible, at its expense, for making any required registrations or
filings with respect to this Agreement and obtaining any necessary governmental
approvals with respect hereto.

     8.9. Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by one party to the other are, for all purposes of Section 365(n) of
Title XI of the United States Code ("Title XI"), licenses of rights to
"intellectual property" as defined in Title XI. During the term of this
Agreement each party shall create and maintain current copies to the extent
practicable of all such intellectual property. If a bankruptcy proceeding is
commenced by or against one party under Title XI, the other party shall be
entitled to a copy of any and all such intellectual property and all embodiments
of such intellectual property, and the same, if not in the possession of such
other party, shall be promptly delivered to it (a) upon such party's written
request following the commencement of such bankruptcy proceeding, unless the
party subject to such bankruptcy proceeding, or its trustee or receiver, elects
within thirty (30) days to continue to perform all of its obligations under this
Agreement, or (b) if not delivered as provided under clause (a) above, upon such
other party's request following the rejection of this Agreement by or on behalf
of the party subject to such bankruptcy proceeding. If a party has taken
possession of all applicable embodiments of the intellectual property of the
other party pursuant to this Section 8.9 and the trustee in bankruptcy of the
other party does not reject this Agreement, the party in possession of such
intellectual property shall return such embodiments upon request. If a party
seeks or involuntarily is placed

                                      -20-
<PAGE>

under Title XI and the trustee rejects this Agreement as contemplated under 11
U.S.C. 365(n)(1), the other party hereby elects, pursuant to Section 365(n) of
Title XI, to retain all rights granted to it under this Agreement to the extent
permitted by law.

     8.10. Use of Name. Neither party shall use the name or trademarks of the
other party, except to the extent that a party is permitted to use the
Confidential Information of the other party pursuant to Article 4, without the
prior written consent of such other party.

     8.11. Further Actions. Each party agrees to execute, acknowledge and
deliver such further instruments, and do such other acts, as may be necessary
and appropriate in order to carry out the purposes and intent of this Agreement.

     8.12. Entire Agreement; Amendment. This Agreement constitutes the entire
and exclusive Agreement between the parties with respect to the subject matter
hereof and supersedes and cancels all previous discussions, agreements,
commitments and writings in respect thereof. No amendment or addition to this
Agreement shall be effective unless reduced to writing and executed by the
authorized representatives of the parties.

     8.13. Arbitration. (a) Solely with respect to any dispute between the
parties to this Agreement (other than any dispute which arises out of or relates
to infringement, validity and/or enforceability of the XOMA Patent Rights) upon
ten (10) days written notice, any party involved in the dispute may initiate
arbitration by giving notice to that effect to the other party or parties
involved in the dispute and by filing the notice with the American Arbitration
Association or its successor organization ("AAA") in accordance with its
Commercial Arbitration Rules. Such dispute shall then be settled by arbitration
in New York, New York, in accordance with the Commercial Arbitration Rules of
the AAA or other rules agreed to by the parties involved in the dispute, by a
panel of three neutral arbitrators, who shall be selected by the parties
involved in the dispute using the procedures for arbitrator selection of the
AAA.

     (b) The parties acknowledge that this Agreement evidences a transaction
involving interstate commerce. Insofar as it applies, the United States
Arbitration Act shall govern the interpretation of, enforcement of, and
proceedings pursuant to the arbitration clause in this Agreement. Except insofar
as the United States Arbitration Act applies to such matters, the agreement to
arbitrate set forth in this Section 8.13 shall be construed, and the legal
relations among the parties shall be determined in accordance with, the
substantive laws of the State of New York.

     (c) The panel shall render its decision and award, including a statement of
reasons upon which such award is based, within thirty (30) days after the
arbitration hearing. The decision of the panel shall be determined by majority
vote among the arbitrators, shall be in writing and shall be binding upon the
parties involved in the dispute, final and non-appealable. Judgment upon the
award rendered by the panel may be entered in any court having jurisdiction
thereof in accordance with Section 8.14(a).

                                      -21-
<PAGE>

     (d) Except as provided under the United States Arbitration Act, no action
at law or in equity based upon any dispute that is subject to arbitration under
this Section 8.13 shall be instituted.

     (e) All expenses of any arbitration pursuant to this Section 8.13,
including fees and expenses of the parties' attorneys, fees and expenses of the
arbitrators, and fees and expenses of any witness or the cost of any proof
produced at the request of the arbitrators, shall be paid by the non-prevailing
party.

     8.14. Venue; Jurisdiction. (a) Any action or proceeding brought by either
party seeking to enforce any provision of, or based on any right arising out of,
this Agreement must be brought against any of the parties in the courts of the
State of New York. Each party (i) hereby irrevocably submits to the jurisdiction
of the state courts of the State of New York and to the jurisdiction of any
United States District Court in the State of New York, for the purpose of any
suit, action, or other proceeding arising out of or based upon this Agreement or
the subject matter hereof brought by any party or its successors or assigns,
(ii) hereby waives, and agrees not to assert, by way of motion, as a defense, or
otherwise, in any such suit, action, or proceeding, any claim that it is not
subject personally to the jurisdiction of the above-named courts, that its
property is exempt or immune from attachment or execution, that the suit, action
or proceeding is brought in an inconvenient forum, that the venue of the suit,
action, or proceeding is improper or that this Agreement or the subject matter
hereof may not be enforced in or by such court, and (iii) hereby waives and
agrees not to seek any review by any court of any other jurisdiction that may be
called upon to grant an enforcement of the judgment of any such New York state
or federal court.

     (b) Process in any action or proceeding seeking to enforce any provision
of, or based on any right arising out of, this Agreement may be served on any
party anywhere in the world. Each party consents to service of process by
registered mail at the address to which notices are to be given and further
consent that any service of process, writ, judgment or other notice of legal
process shall be deemed and held in every respect to be effectively served upon
it in connection with proceedings in the State of New York, if delivered to CT
Corporation System, whose current address is 111 Eighth Avenue, 13th Floor, New
York, New York 10011, which each party irrevocably designates and appoints as
its authorized agent for the service of process in the courts in the State of
New York. Nothing herein shall affect the right of a party to serve process in
any other manner permitted by applicable law. Each party further agrees that
final judgment against it in any such action or proceeding arising out of or
relating to this Agreement shall be conclusive and may be enforced in any other
jurisdiction within or outside the United States of America by suit on the
judgment, a certified or exemplified copy of which shall be conclusive evidence
of the fact and of the amount of its liability.

     (c) Each party agrees that it shall not, and that it shall instruct those
in its control not to, take any action to frustrate or prevent the enforcement
of any writ, decree, final judgment, award (arbitral or otherwise) or order
entered against it with respect to this Agreement or the XOMA Patent Rights and
shall agree to be bound thereby as if issued or executed by a competent judicial
tribunal having personal jurisdiction situated in its country of residence or
domicile.

                                      -22-
<PAGE>

     8.15. Force Majeure. Neither party shall be liable for failure of or delay
in performing obligations set forth in this Agreement, and neither shall be
deemed in breach of its obligations, if such failure or delay is due to natural
disasters or any causes beyond the reasonable control of such party. In event of
such force majeure, the party affected thereby shall use reasonable efforts to
cure or overcome the same and resume performance of its obligations hereunder.

     8.16. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                      -23-
<PAGE>

     IN WITNESS WHEREOF, XOMA and MORPHOSYS have executed this Agreement in
duplicate originals by duly authorized officers.

MORPHOSYS AG                         XOMA IRELAND LIMITED

By:                                  By:
    -------------------------             ------------------------------------
      Name:                               Alan Kane, Director
      Title:                              duly authorized for and on behalf of
                                          XOMA Ireland
                                          Limited in the
                                          presence of:

By:
    --------------------------
      Name:
      Title:

                                      -24-
<PAGE>

                                                                   Schedule 1.17

                                  PATENT RIGHTS

Title:      Modular Assembly of Antibody Genes, Antibodies Prepared Thereby
            and Use
Inventors:  Robinson, Liu, Horwitz, Wall, Better

1)   Based on PCT/US86/02269, which is a continuation-in-part of U.S. Serial No.
     06/793,980 filed November 1, 1985 (abandoned).

         COUNTRY                 SERIAL NO.                 PATENT NO.
         -------                 ----------                 ----------
         *United States          06/793,980
         Australia               65981/86                   Issued  606,320
         Canada                  521,909                    Abandoned
         Denmark                 3385/87                    Pending
         Taiwan                  75105650                   Issued  51922
         *United States          06/086,266

2)   Based on PCT/US88/02514, which corresponds to U.S. Serial No. 07/077,528,
     which is a continuation-in-part of 06/086,266 (abandoned), which is a
     continuation-in-part of U.S. Serial No. 06/793,980 (abandoned).

        COUNTRY                  SERIAL NO.                 PATENT NO.
        -------                  ----------                 ----------
        Australia                23244/88                   Issued   632,462
        Austria                  EP 88907510.7              Granted EP/0371998
        Belgium                  EP 88907510.7              Granted EP/0371998
        Canada                   572,398                    Pending
        Denmark                  192/90                     Pending
        Europe                   EP 88907510.7              Granted EP/0371998
        Europe                   EP 95119798.7              Granted EP/0731167
        France                   EP 88907510.7              Granted EP/0371998
        Germany                  EP 88907510.7              Granted EP/0371998
        Italy                    EP 88907510.7              Granted EP/0371998
        Japan                    506481/88                  Granted 2991720
        Luxembourg               EP 88907510.7              Granted EP/0371998
        Netherlands              EP 88907510.7              Granted EP/0371998
        Sweden                   EP 88907510.7              Granted EP/0371998
        Switzerland/
        Liechtenstein            EP 88907510.7              Granted EP/0371998
        United Kingdom           EP 88907510.7              Granted EP/0371998
        Europe                   EP 93100041.8              Granted EP/0550400

                                       -1-
<PAGE>

        COUNTRY                  SERIAL NO.                 PATENT NO.
        -------                  ----------                 ----------
        Austria                  EP 93100041.8              Granted EP/0550400
        Belgium                  EP 93100041.8              Granted EP/0550400
        France                   EP 93100041.8              Granted EP/0550400
        Germany                  EP 93100041.8              Granted EP/0550400
        Italy                    EP 93100041.8              Granted EP/0550400
        Luxembourg               EP 93100041.8              Granted EP/0550400
        Netherlands              EP 93100041.8              Granted EP/0550400
        Sweden                   EP 93100041.8              Granted EP/0550400
        Switzerland/
        Liechtenstein            EP 93100041.8              Granted EP/0550400
        United Kingdom           EP 93100041.8              Granted EP/0550400
        *United States           07/077,528

3)   Based on U.S. Serial No. 07/501,092 filed March 29, 1990, which is a
     continuation-in-part of U.S. Serial No. 07/077,528 (Modular Assembly of
     Antibody Genes, Antibodies Prepared Thereby and Use; Robinson, Liu,
     Horwitz, Wall, Better) and of U.S. Serial No. 07/142,039 (Novel Plasmid
     Vector with Pectate Lyase Signal Sequence; Lei, Wilcox).

        COUNTRY                  SERIAL NO.                 PATENT NO.
        -------                  ----------                 ----------
        *United States           07/501,092
        *United States           07/987,555
        *United States           07/870,404
        *United States           08/020,671
        United States            08/235,225                 5,618,920
        United States            08/299,085                 5,595,898
        United States            08/357,234                 5,576,195
        United States            08/472,696                 5,846,818
        United States            08/472,691                 6,204,023
        United States            08/467,140                 5,698,435
        United States            08/450,731                 5,693,493
        United States            08/466,203                 5,698,417

*Cases abandoned in favor of a continuing application.

                                      -2-
<PAGE>

                                                                    Schedule 2.8

MorphoSys Partnerships
----------------------

[*]

                                      -3-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]